Drug Utilization Study Of Diuretics In Hepatic Cirrhosis Patient With Ascites At Airlangga University Hospital Surabaya
Year: 2018
Type: conference-paper
Study design: Observational Study
Abstract: Ascites is an accumulation of fluid in the peritoneal space and one of the first signs of decompensation of liver disease. Ascites is one of the complications experienced by patients with hepatic cirrhosis. Therapy commonly used for ascites is diuretics, along with salt restriction in the diet. Potassium-sparing diuretics, especially spironolactone and loop diuretics, especially furosemide, are the main pharmacological therapies for ascites. The purpose of this study was to examine the characteristics distribution of hepatic cirrhosis patients, to assess the profile of the use of diuretic drugs during hospitalization, and to determine the possibility of a Drug Related Problem (DRP) on diuretic therapy for patients with ascites at Airlangga University Hospital (RSUA) Surabaya. The research was conducted with non-experimental methods or observations, it was subsequently analyzed descriptively. Data collection was carried out in non-random and time limited sampling in the period of 1 January 2013 - 31 March 2017 in the Inpatient Room of Internal Medicine Department at RSUA Surabaya and was declared as ethically feasible. Based on the results of 45 SH samples with complications of ascites, the most common characteristics of hepatic cirrhosis patients were men by 53.33%, the highest age range was 45-64 years at 75.56%, while the highest complication was hypoalbumin with the percentage of 26.67% and the longest treatment duration was 6-10 days at 46.67%.The therapeutic profile of diuretics in this study, namely the use of furosemide as a single therapy with the percentage of 17.78% and single spironolactone therapy of 2.22% and combination therapy of spironolactone with furosemide with the percentage of 80.00 %. The most widely used furosemide was intravenous use with a daily dose of 1x20mg 57.78%, while spironolactone was the most widely used in oral use with a daily dose of 1x100mg 44.44%. Drug Related Problems (DRP) that occuedr including potential drug interactions found in concomitant use between spironolactone and potassium preparations with the percentage of 24.44%. No actual drug interactions and side effects were found in this study.
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2913787018